Director converts RSUs into 972 INOVIO (NASDAQ: INO) shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
INOVIO PHARMACEUTICALS director David B. Weiner acquired 972 shares of common stock through an RSU conversion. On February 26, 2026, 972 restricted stock units vested and were exercised at $0.00 per share, converting into 972 common shares.
These units were part of a 2,916‑unit grant made on February 27, 2023, vesting in three equal installments of 972 units on February 26 of 2024, 2025, and 2026. After this transaction, Weiner directly holds 87,592 shares of INOVIO common stock, and no restricted stock units from this grant remain outstanding.
Positive
- None.
Negative
- None.
Insider Trade Summary
972 shares exercised/converted
Mixed
2 txns
Insider
Weiner David B.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 972 | $0.00 | -- |
| Exercise | Common Stock | 972 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Unit — 0 shares (Direct);
Common Stock — 87,592 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did INOVIO (INO) director David B. Weiner report?
David B. Weiner reported acquiring 972 INOVIO common shares through conversion of restricted stock units. The RSUs vested on February 26, 2026 and were exercised at zero cost, increasing his directly held common stock position to 87,592 shares after the transaction.
What was the vesting schedule for David Weiner’s INOVIO (INO) RSU grant?
The 2,916 restricted stock units granted on February 27, 2023 vested in three installments. 972 units vested on February 26, 2024; another 972 on February 26, 2025; and the final 972 on February 26, 2026, which were converted into common stock in this filing.